Treating Primary Uveal Melanoma

Treating Primary Uveal Melanoma

Introduction

The most frequently encountered type of eye tumour (uveal tumour) is the melanoma.

Following extensive research involving multiple specialists, such as an ophthalmologist and a surgeon, a final diagnosis will be established. Radiation treatment (radiotherapy) plays an important role in your overall treatment: in certain cases, it may help preserve your eyesight. 

Radiotherapy and Proton Therapy for Uveal Tumours

Modern radiation treatment technology uses photons. This photon radiation may influence the healthy tissue surrounding the tumour, such as the retina. This may lead to retroactive worsened vision or blindness in the long run. In situations like these, proton therapy may be a good alternative option, which can reduce the risk of these complications in some cases. Proton therapy is currently  not available in the Netherlands. 

Expected Availability

It is expected that the first treatments of primary uveal melanoma using proton therapy in the Netherlands will become available as of the end of 2017.
The HollandPTC is the designated treatment location for this procedure in the Netherlands. HollandPTC is an independent clinic and research centre, and a collaborative effort of the TU Delft, the Leiden University Medical Centre and the Erasmus Medical Centre.

The UMC Groningen Proton Therapy Centre will not be treating uveal tumours.
The UMCG Radiotherapy department will be referring patients with primary uveal melanoma to the HollandPTC.
For more information, please visit www.Hollandptc.nl.

Until then, patients with primary uveal melanoma can be referred abroad, such as to the Paul Scherrer Instituut (PSI) in Villingen (Switzerland).